Why the study?
Does exogenous B-type natriuretic peptide (BNP) improve perioperative management in cardiac surgery patients?
Does exogenous B-type natriuretic peptide (BNP) improve perioperative management in cardiac surgery patients?
Administration of exogenous BNP is being investigated as a supportive neurohormonal therapy to enhance perioperative management in cardiac surgery patients.
Remains investigational for perioperative cardiac surgery support; leaves open efficacy and safety pending randomized trials.
Both heart failure (HF) and cardiac surgery with cardiopulmonary bypass result in a release of neurohormones, with a variety of physiologic effects. Administration of exogenous B-type natriuretic peptide (BNP) has beneficial hemodynamic effects and reduces the level of several neurohormones in HF patients. BNP is currently being investigated in the perioperative management of cardiac surgery patients and may be especially beneficial for patients with ventricular dysfunction, pulmonary hypertension, or renal dysfunction. Using a neurohormonal approach to supportive therapy may enhance future strategies for patients undergoing cardiac surgery, especially those at greatest risk for complications.
No takes yet. Share an insight, caveat, or question.
Moazami et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: